Hereditary Malignant Urinary System Neoplasm

Hereditary Malignant Urinary System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 40%
Top sponsor: Jonsson Comprehensive Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04981509	Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer	recruiting	Phase 2	65	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT03401788	A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)	active not recruiting	Phase 2	50	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY